CytoReason Licenses IBD Disease Model to Sanofi in Expanded Alliance

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Resistance-Evasive Antibiotic for Genes-Free Clinics

In a startling figure, multidrug-resistant bacteria kill almost 5...

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

CytoReason, a pioneer in computational disease modeling, expanded its collaboration with Sanofi. The multiyear collaboration will further Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets. In 2021, the companies initiated a project with Sanofi using cell-centered models to suggest mechanistic insights for asthma endotypes.

Under the terms of the expanded agreement, Sanofi will pay CytoReason an undisclosed multimillion dollar amount. Sanofi has previously applied Cytoreason’s cell-centered model to better understand asthma patient subtypes.

“It’s exciting to see the growing adoption of our technology by world-leading pharma companies,” said David Harel, CEO & Co-founder of CytoReason. “By harnessing our game-changing AI capabilities, we hope to help Sanofi’s scientists identify novel and personalized targets in IBD, and to prioritize targets in their pipeline. CytoReason’s innovative machine learning methods, supported by proprietary human data, is paving the way for top pharma and biotech companies to reimagine drug R&D.”

“At Sanofi, our drug discovery strategy is driven by precision medicine. We seek to describe diseases at the molecular and cellular level to understand the causes underpinning different patient responses to treatments, and to ultimately match the right medicine to the right patient,” said Emanuele de Rinaldis, Global Head of Precision Medicine and Computational Biology. “We are pleased to expand our collaboration with CytoReason and look forward to applying insights from this collaboration as we work to develop new treatments for patients with IBD.”

 

Latest stories

Related stories

Resistance-Evasive Antibiotic for Genes-Free Clinics

In a startling figure, multidrug-resistant bacteria kill almost 5...

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back